Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment Nipocalimab, a novel treatment developed by Johnson & Johnson, has received Fast Track designation from the FDA for lupus therapy, addressing critical patient needs.

Johnson & Johnson's Nipocalimab Receives Fast Track Designation for SLE Treatment #United_States #Johnson_&_Johnson #Spring_House #nipocalimab #Systemic_Lupus

Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference Mallinckrodt highlights real-world data on Acthar Gel for systemic lupus erythematosus at LUPUS 2025, showcasing treatment effectiveness and patient profiles.

Real-World Outcomes of Acthar Gel Presented at LUPUS 2025 Conference #Canada #Toronto #Mallinckrodt #Acthar_Gel #Systemic_Lupus